103 Results

People

  1. Old
    Old
  2. Livingston
    Livingston
  3. Ritter
    Ritter
  4. Gnjatic
    Gnjatic
  5. Ragupathi
    Ragupathi
  6. Houghton
    Houghton
  7. Wolchok
    Wolchok
  8. Jungbluth
    Jungbluth
  9. Slovin
    Slovin
  10. Allison
    Allison

Groups

  1. Department of Medicine (52)
  2. Solid Tumor Oncology Division (49)
  3. Melanoma and Immunotherapeutics Service (34)
  4. GSK Faculty (25)
  5. Melanoma Disease Management Team (21)
  6. Sloan Kettering Institute Postdocs (20)
  7. Sloan Kettering Institute Faculty (19)
  8. Hematologic Malignancies, Division of (17)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (16)
  10. Biostatistics Service (12)
  1. "cancer immunization"
Formats
  1. Journal Article (96)
  2. Conference Paper (3)
  3. Review (3)
  4. Editorial (1)
Groups
  1. Department of Medicine (52)
  2. Solid Tumor Oncology Division (49)
  3. Melanoma and Immunotherapeutics Service (34)
  4. GSK Faculty (25)
  5. Melanoma Disease Management Team (21)
  6. Sloan Kettering Institute Postdocs (20)

More Groups

People
  1. Lloyd Old (20)
  2. Philip Livingston (18)
  3. Jedd Wolchok (14)
  4. Gerd Ritter (13)
  5. Govindaswami Ragupathi (11)
  6. Sacha Gnjatic (11)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (3)
  5. 2020 (2)
  6. 2015 (4)

More Years

Publications
  1. Clinical Cancer Research (12)
  2. Cancer Immunology, Immunotherapy (8)
  3. Proceedings of the National Academy of Sciences of the United States of America (7)
  4. International Journal of Cancer (6)
  5. Cancer Immunity (4)
  6. Cancer Research (3)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. Elsevier Inc. (14)
  3. Springer (12)
  4. Nature Publishing Group (8)
  5. Lippincott Williams & Wilkins (7)
  6. National Academy of Sciences (7)

More Publishers

Results (103)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of preexisting MAGE-A3-specific CD4(+) T cells in cancer patients and healthy individuals and their activation by protein vaccination
    Journal Article

    Tsuji, T.; Altorki, N. K.; Ritter, G.; Old, L. J.; Gnjatic, S.
    Journal of Immunology (2009)

    Fulltext@MSK | Save
  • Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma
    Journal Article

    Riener, M. O.; Wild, P. J.; Soll, C.; Knuth, A.; Jin, B.; Jungbluth, A.; Hellerbrand, C.; Clavien, P. A.; Moch, H.; Jochum, W.
    International Journal of Cancer (2009)

    Fulltext@MSK | Save
  • Nonglycosidic agonists of invariant NKT cells for use as vaccine adjuvants
    Journal Article

    Reddy, B. G.; Silk, J. D.; Salio, M.; Balamurugan, R.; Shepherd, D.; Ritter, G.; Cerundolo, V.; Schmidt, R. R.
    ChemMedChem (2009)

    Fulltext@MSK | Save
  • Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists
    Journal Article

    Peggs, K. S.; Quezada, S. A.; Allison, J. P.
    Clinical and Experimental Immunology (2009)

    Fulltext@MSK | Save
  • Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation
    Journal Article

    Jenq, R. R.; King, C. G.; Volk, C.; Suh, D.; Smith, O. M.; Rao, U. K.; Yim, N. L.; Holland, A. M.; Lu, S. X.; Zakrzewski, J. L.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Improving the efficacy of cancer immunotherapy
    Journal Article

    Copier, J.; Dalgleish, A. G.; Britten, C. M.; Finke, L. H.; Gaudernack, G.; Gnjatic, S.; Kallen, K.; Kiessling, R.; Schuessler-Lenz, M.; Singh, H.; more...
    European Journal of Cancer (2009)

    Fulltext@MSK | Save
  • HLA class i-associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine
    Journal Article

    Bioley, G.; Guillaume, P.; Luescher, I.; Yeh, A.; Dupont, B.; Bhardwaj, N.; Mears, G.; Old, L. J.; Valmori, D.; Ayyoub, M.
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save
  • Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire
    Journal Article

    Bioley, G.; Dousset, C.; Yeh, A.; Dupont, B.; Bhardwaj, N.; Mears, G.; Old, L. J.; Ayyoub, M.; Valmori, D.
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save
  • Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors
    Journal Article

    Bioley, G.; Guillaume, P.; Luescher, I.; Bhardwaj, N.; Mears, G.; Old, L.; Valmori, D.; Ayyoub, M.
    Journal of Immunotherapy (2009)

    Fulltext@MSK | Save
  • Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination
    Journal Article

    Wada, H.; Sato, E.; Uenaka, A.; Isobe, M.; Kawabata, R.; Nakamura, Y.; Iwae, S.; Yonezawa, K.; Yamasaki, M.; Miyata, H.; more...
    International Journal of Cancer (2008)

    Fulltext@MSK | Save